Clinical trials: Androgen Deprivation Therapy
Prostate Cancer, Hot Flashes
Embr Thermal Device for Hot Flash Management in Prostate Cancer
This study is being conducted to evaluate if the Embr thermal device is useful for men who experience bothersome hot flashes as a result of prostate cancer treatment.
- Trial name
- NCT04892914
- Testing
- Embr thermal device
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Embr Labs, Inc.
Prostate Cancer Patients, Androgen Deprivation Therapy
Effects of Combined Training in Prostate Cancer Patients
Prostate cancer is the most prevalent type among men in Brazil, after non-melanoma skin cancer. One of the main treatment approaches is androgen suppression therapy (AST), which, although effective in controlling tumor growth…
- Trial name
- Proactive (NCT07680920)
- Testing
- Combined training
- Volunteers
- 46 people
- Sponsor
- Universidade Federal de Santa Catarina
Prostate Cancer
Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NRR (NCT00225420)
- Testing
- docetaxel, leuprolide acetate, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Prostate Cancer
Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer
Stereotactic body radiation therapy (SBRT) is a very precise form of radiation therapy that allows the physician to deliver more radiation dose in a single session.
- Trial name
- NCT03056638
- Testing
- Degarelix, stereotactic body radiosurgery (SBRT)
- Where
- 10 sites in United States
- Volunteers
- 56 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer
The goal of this clinical trial is to evaluate the outcomes of a shorter treatment duration (12 months) with an androgen receptor pathway inhibitor (ARPI), in this study Apalutamide or Enzalutamide, in patients with low-volume…
- Trial name
- Apa/Enza-short (NCT07260435)
- Testing
- ADT plus only 12 months of ARPI, ADT plus continued ARPI
- Where
- 26 sites in Netherlands
- Volunteers
- 400 people
- Sponsor
- Nick Beije
Pain, Prostate Cancer
Androgen Ablation With or Without Docetaxel in Treating Patients With Advanced Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation therapy may lessen the amount of androgens made by the body.
- Trial name
- NCT00796458
- Testing
- docetaxel, releasing hormone agonist therapy
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- A.O.U. San Giovanni Battista di Torino, Italy
Prostate Cancer
Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer
RATIONALE: Vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying vaccine therapy to see how well it works compared with a…
- Trial name
- NCT00514072
- Testing
- BCG vaccine, prostate cancer vaccine ONY-P1
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Kael-GemVax Co., Ltd.
Prostate Cancer
Micro RNAs to Predict Response to Androgen Deprivation Therapy
Identify exosomal micro RNA that predict responses to ADT
- Trial name
- NCT02366494
- Testing
- Bicalutamide, Leuprolide, Goserelin
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Medical College of Wisconsin
Prostate Cancer
Tecemotide (L-BLP25) in Prostate Cancer
This study examines tecemotide (L-BLP25) in combination with standard treatment for prostate cancer.
- Trial name
- NCT01496131
- Testing
- Radiation therapy, Goserelin, Cyclophosphamide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- EMD Serono
Prostate Cancer
Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)
Less than 20% of men in whom prostate cancer is diagnosed early die from it. Cardiovascular disease is the most common cause of death in men with early prostate cancer.
- Trial name
- NCT01006395
- Testing
- Zoledronic acid
- Where
- Australia
- Volunteers
- 64 people
- Sponsor
- Austin Health
Prostate Cancer
A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer
The purpose of this study is to find out whether combining a shorter than standard course of ADT with standard prostate brachytherapy and hypofractionated external beam radiation therapy is a safe and effective way to prevent…
- Trial name
- NCT05100472
- Testing
- Androgen deprivation therapy (ADT), Brachytherapy, Hypofractionated pelvic External beam radiation
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older
The purpose of this study is to find out if therapy with hormones (such as Lupron, Casodex, Zolodex or Degarelix) change a person's thinking abilities.
- Trial name
- NCT00579072
- Testing
- Questionaires, fMRI scan (optional)
- Where
- 2 sites in United States
- Volunteers
- 230 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
The purpose of this research study is to assess the efficacy of antiangiogenic therapy (bevacizumab) and androgen deprivation versus androgen deprivation alone at the time of minimal systemic disease (based on rising PSA without…
- Trial name
- NCT00776594
- Testing
- Androgen Deprivation Therapy, bicalutamide, bevacizumab
- Where
- 8 sites in United States
- Volunteers
- 102 people
- Sponsor
- Dana-Farber Cancer Institute
Adenocarcinoma of Prostate, Progression of Prostate Cancer
A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
The objective of this study is to assess the effect of neoadjuvant cabazitaxel and pelvic radiotherapy in combination with androgen deprivation therapy (ADT)-radiotherapy on clinical progression-free survival in patients with…
- Trial name
- PEACE2 (NCT01952223)
- Testing
- Cabazitaxel, Pelvic radiotherapy, prostate radiotherapy
- Where
- France
- Volunteers
- 761 people
- Sponsor
- UNICANCER
Prostate Cancer
TherApeutics in Early ProState Cancer (TAPS02)
This is a phase 2, randomised, multicentre, double-blind, placebo-controlled trial investigating the use of short term androgen deprivation therapy in the form of apalutamide (Erleada) in men on active surveillance for prostate…
- Trial name
- NCT05191680
- Testing
- Apalutamide Oral Tablet [Erleada]
- Where
- 6 sites in United Kingdom
- Volunteers
- 90 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Prostate Cancer
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00003653
- Testing
- bicalutamide, buserelin, cyproterone acetate
- Where
- 29 sites in Canada
- Volunteers
- 1,386 people
- Sponsor
- NCIC Clinical Trials Group
Prostate Cancer
Pembro With Radiation With or Without Olaparib
This trial will evaluate whether the immune-sensitizing effects of immunotherapy (Pembrolizumab) and radiation with or without a PARP-inhibitor (Olaparib) will increase the effects of immunotherapy in men with high-risk localized…
- Trial name
- NCT05568550
- Testing
- Pembrolizumab, Olaparib, Androgen Deprivation Therapy
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Zin W Myint
Prostate Cancer
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00016913
- Testing
- carboplatin, estramustine, paclitaxel
- Where
- 23 sites in United States
- Volunteers
- 34 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy
The purpose of this research is to determine the effect of timing of Zometa® administration on bone mineral density of the lumbar spine and femoral neck in men undergoing androgen deprivation therapy for prostate adenocarcinoma.
- Trial name
- NCT00582556
- Testing
- Zometa
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Wisconsin, Madison
High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
This phase II trial tests how well pembrolizumab along with standard of care androgen deprivation therapy, with bicalutamide and gonadotropin releasing hormone agonist, and radiotherapy for the treatment of patients with high…
- Conditions
- High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
- Trial name
- NCT06528210
- Testing
- Gonadotropin Releasing Hormone Agonists and Antagonists, Bicalutamide, Biopsy Procedure
- Sponsor
- OHSU Knight Cancer Institute